Patent US20070109412A1 successfully refreshed from Google Patents.
US5019368A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Detection of necrotic malignant tissue and associated therapy
Assignee: MIDCAP FUNDING III LLC
•
Filing: 1989-02-23
•
Granted: 1991-05-28
•
Expires: 2009-02-23
Abstract
Abstract Disclosed is a method for enhancing the effects of therapy that kills malignant cells in vivo comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of a mammal but not to external cellular components, wherein the monoclonal antibody is attached to an antineoplastic agent; initiating therapy in a mammal to kill malignant cells in vivo, thereby causing some of the malignant cells to become necrotic; and administering the antibodies to the mammal. The antibodies bind to the necrotic malignant cells thereby delivering antineoplastic agent to surrounding cells. Also disclosed is a method of de novo therapy comprising administration of antibody-antineoplastic agent conjugate such that antineoplastic agent is delivered to the tumor. Also disclosed are antibodies for use with the foregoing methods and for use with diagnositc methods.
Inventors
- 👤 Alan L. Epstein
- 👤 Clive R. Taylor
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 00:49
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/5758; G01N33/57595; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6835; A61K47/6851; A61K49/00; A61K49/04; A61K49/06; A61K49/08; A61K49/10; A61K49/14; A61K49/16; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1018; A61K51/1045; C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3061; A61K2121/00; A61K2123/00; A61K38/00; C07K2317/00; C07K2317/50; C07K2317/54
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
114 words
A method for enhancing in a mammal the effects of therapy that kills malignant cells in vivo, comprising the steps of: obtaining an antibody specific to an insoluble internal cellular antigen present in degenerating neoplastic cells or cells which may be induced to be permeable that is not present on the exterior of a living cell, wherein said antibody has directly or indirectly bound thereto an antineoplastic agent; initiating therapy in said mammal to kill malignant cells in vivo, thereby causing some of said malignant cells to become necrotic; and administering said antibodies to said mammal whereby said antibodies become bound to said necrotic malignangt cells, thereby delivering said antineoplastic agent to surrounding cells.
Claim 2
Independent Claim
114 words
A method for enhancing in a mammal the effects of therapy that kills malignant cells in vivo, comprising the steps of: obtaining an antibody specific to an insoluble internal cellular antigen present in degenerating neoplastic cells or cells which may be induced to be permeable that is not present on the exterior of a living cell, wherein said antibody has directly or indirectly bound thereto an antineoplastic agent; initiating therapy in said mammal to kill malignant cells in vivo, thereby causing some of said malignant cells to become necrotic; and administering said antibodies to said mammal whereby said antibodies become bound to said necrotic malignangt cells, thereby delivering said antineoplastic agent to surrounding cells.
Claim 3
Dependent Claim
38 words
A method of claim 1, wherein said antineoplastic agent is selected from the group consisting of a cytotoxic agent, a toxin, a biological response modifier, a radiosensitizing compound, an alpha-emitting radionuclide, a beta-emitting radionuclide, and an antiproliferative agent.
Claim 4
Dependent Claim
12 words
The method of claim 1, wherein said cells are killed with radiation.
Claim 5
Dependent Claim
12 words
The method of claim 1, wherein said cells are killed with chemotherapy.
Claim 6
Dependent Claim
13 words
The method of claim 1, wherein said cells are killed by immunological techniques.
Claim 7
Independent Claim
153 words
A method for delivering primary, de novo therapy to a wide variety of cancer types, both primary tumors and metastases, to kill neoplastic cells in vivo in a mammal, comprising the steps of: obtaining an antibody specific to an insoluble internal cellular antigen, wherein said antibody is obtained by screening a library of antibodies generated to insoluble intracellular antigens, and selecting those antibodies that are specific to insoluble intracellular antigen present in both neoplastic and normal cells but not present on the exterior of living cells and that is not released into the general circulation upon cell death, wherein said antibody has directly or indirectly bound thereto an antineoplastic agent; and initiating therapy directly by administering said antibody-antineoplastic agent conjugate to said mammal, whereby said antibody conjugate becomes selectively bound to permeable cells present within primary or metastatic neoplasms in said mammal, thereby delivering said antineoplastic agent to cells surrounding said permeable cells.
Claim 8
Independent Claim
153 words
A method for delivering primary, de novo therapy to a wide variety of cancer types, both primary tumors and metastases, to kill neoplastic cells in vivo in a mammal, comprising the steps of: obtaining an antibody specific to an insoluble internal cellular antigen, wherein said antibody is obtained by screening a library of antibodies generated to insoluble intracellular antigens, and selecting those antibodies that are specific to insoluble intracellular antigen present in both neoplastic and normal cells but not present on the exterior of living cells and that is not released into the general circulation upon cell death, wherein said antibody has directly or indirectly bound thereto an antineoplastic agent; and initiating therapy directly by administering said antibody-antineoplastic agent conjugate to said mammal, whereby said antibody conjugate becomes selectively bound to permeable cells present within primary or metastatic neoplasms in said mammal, thereby delivering said antineoplastic agent to cells surrounding said permeable cells.
Claim 9
Dependent Claim
38 words
The method of claim 6, wherein said antineoplastic agent is selected from the group consisting of a cytotoxic agent, a toxin, a biological response modifier, a radiosensitizing compound, an alpha-emitting radionuclide, a beta-emitting radionuclide, and an antiproliferative agent.
Claim 10
Dependent Claim
61 words
A monoclonal antibody to an insoluble intracellular antigen present in cells which may be induced to be permeable, or in cell ghosts of substantially all neoplastic and normal cells, but not present on the exterior of living cells of said mammal, wherein said antibody is bound to a moiety comprising at least in part an alpha-emitting radionuclide or a beta-emitting radionuclide.
Claim 11
Dependent Claim
61 words
A monoclonal antibody to an insoluble intracellular antigen present in cells which may be induced to be permeable, or in cell ghosts of substantially all neoplastic and normal cells, but not present on the exterior of living cells of said mammal, wherein said antibody is bound to a moiety comprising at least in part an alpha-emitting radionuclide or a beta-emitting radionuclide.
Claim 12
Dependent Claim
67 words
A monoclonal antibody to an insoluble intracellular antigen present in cells which may be induced to be permeable, or in cell ghosts of substantially all neoplastic and normal cells of a mammal, but not present on the exterior of living cells of said mammal, wherein said antibody is bound to a moiety comprising at least in part a chemotherapeutic or immunotherapeutic agent or a biological response modifier.
Claim 13
Dependent Claim
67 words
A monoclonal antibody to an insoluble intracellular antigen present in cells which may be induced to be permeable, or in cell ghosts of substantially all neoplastic and normal cells of a mammal, but not present on the exterior of living cells of said mammal, wherein said antibody is bound to a moiety comprising at least in part a chemotherapeutic or immunotherapeutic agent or a biological response modifier.
References Cited (Backward Citations)
GB2067286A
Cited
US4331647A
Cited
US4361544A
Cited
US4460561A
Cited
US4460559A
Cited
US4628027A
Cited
US4699877A
Cited
US4499183A
Cited
US4613576A
Cited
US4735210A
Cited
US4861581A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-05-27 | 1994-11-26 | 1995-05-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-05-27 | 1998-11-26 | 1999-05-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-05-27 | 2002-11-26 | 2003-05-28 | $7700.00 | Window Closed / Lapsed |